Chimerix (NASDAQ:CMRX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $11.00 target price on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on CMRX. Robert W. Baird […]